167 related articles for article (PubMed ID: 32030448)
1. Quick complete response achievement with venetoclax and azacitidine in a case of relapsed disseminated blastic plasmacytoid dendritic cell neoplasm.
Piccini M; Loscocco GG; Gianfaldoni G; Grieco P; Palmieri G; Pilerci S; Scappini B; Bosi A
Ann Hematol; 2020 Apr; 99(4):907-909. PubMed ID: 32030448
[No Abstract] [Full Text] [Related]
2. Tagraxofusp followed by combined azacitidine and venetoclax in blastic plasmacytoid dendritic cell neoplasm: A case report and literature review.
Samhouri Y; Ursu S; Dutton N; Tanvi V; Fazal S
J Oncol Pharm Pract; 2021 Jun; 27(4):990-995. PubMed ID: 32847479
[TBL] [Abstract][Full Text] [Related]
3. Venetoclax to treat relapsed blastic plasmacytoid dendritic cell neoplasm: A case-report and review of literature.
Beziat G; Ysebaert L; Gaudin C; Steinmeyer Z; Balardy L
Leuk Res; 2019 Oct; 85():106199. PubMed ID: 31415942
[No Abstract] [Full Text] [Related]
4. Venetoclax monotherapy for cutaneous blastic plasmacytoid dendritic cell neoplasm.
Schwede M; Tan IT; Atibalentja DF; Dickman MM; Rieger KE; Mannis GN
Ann Hematol; 2020 Dec; 99(12):2973-2975. PubMed ID: 32968828
[No Abstract] [Full Text] [Related]
5. Combination of Tagraxofusp and Azacitidine Is an Effective Option for Relapsed Blastic Plasmacytoid Dendritic Cell Neoplasm After Allogeneic Hematopoietic Stem-Cell Transplantation.
Wang SY; Thomassen K; Kurch L; Opitz S; Franke GN; Bach E; Platzbecker U; Kayser S
Clin Lymphoma Myeloma Leuk; 2021 Jul; 21(7):e579-e582. PubMed ID: 33795208
[No Abstract] [Full Text] [Related]
6. Low-dose venetoclax combined with azacitidine for blastic plasmacytoid dendritic cell neoplasm: a case report and literature review.
Wang Q; Zhao Y; Zang X; Zhou G; Liu Y; Feng Q; Li X; Wang W; Dong X; Liu X; Peng J; Liu C
Ann Hematol; 2024 Mar; 103(3):999-1005. PubMed ID: 38285081
[TBL] [Abstract][Full Text] [Related]
7. Venetoclax in a Patient with a Blastic Plasmacytoid Dendritic-Cell Neoplasm.
Agha ME; Monaghan SA; Swerdlow SH
N Engl J Med; 2018 Oct; 379(15):1479-1481. PubMed ID: 30304659
[No Abstract] [Full Text] [Related]
8. Achievement of rapid complete remission in an 87-year-old female patient with azacytidine-venetoclax for blastic plasmacytoid dendritic cell neoplasm.
Le Calloch R; Arnaud B; Le Clech L; Hutin P; Salmon F; Garnache Ottou F; Ianotto JC; Laribi K
Ann Hematol; 2022 Jun; 101(6):1347-1349. PubMed ID: 35249131
[No Abstract] [Full Text] [Related]
9. Venetoclax with decitabine or azacitidine for AML.
Das M
Lancet Oncol; 2018 Dec; 19(12):e672. PubMed ID: 30392809
[No Abstract] [Full Text] [Related]
10. Blastic Plasmacytoid Dendritic Cell Neoplasm Is Dependent on BCL2 and Sensitive to Venetoclax.
Montero J; Stephansky J; Cai T; Griffin GK; Cabal-Hierro L; Togami K; Hogdal LJ; Galinsky I; Morgan EA; Aster JC; Davids MS; LeBoeuf NR; Stone RM; Konopleva M; Pemmaraju N; Letai A; Lane AA
Cancer Discov; 2017 Feb; 7(2):156-164. PubMed ID: 27986708
[TBL] [Abstract][Full Text] [Related]
11. Venetoclax in relapsed/refractory blastic plasmacytoid dendritic cell neoplasm with central nervous system involvement: a case report and review of the literature.
Albiol N; Novelli S; Mozos A; Pratcorona M; Martino R; Sierra J
J Med Case Rep; 2021 Jun; 15(1):326. PubMed ID: 34172079
[TBL] [Abstract][Full Text] [Related]
12. RUNX1 mutations correlate with response to venetoclax combination therapies in relapsed/refractory acute myeloid leukemia.
Chow S; Tang K; Al-Abri M; Hall V; Tremblay-Lemay R; Rashedi I; Tsui H; Chan SM
Leuk Res; 2021 Dec; 111():106735. PubMed ID: 34735933
[No Abstract] [Full Text] [Related]
13. Hypomethylating agents and venetoclax in acute myeloid leukemia.
DiNardo CD
Clin Adv Hematol Oncol; 2021 Feb; 19(2):82-83. PubMed ID: 33596188
[No Abstract] [Full Text] [Related]
14. A Case of Cutaneous Blastic Plasmacytoid Dendritic Cell Neoplasm Treated With a Bcl-2 Inhibitor.
Egger A; Coello D; Kirsner RS; Brehm JE
J Drugs Dermatol; 2021 May; 20(5):550-551. PubMed ID: 33938687
[TBL] [Abstract][Full Text] [Related]
15. Real-world experience of venetoclax with azacitidine for untreated patients with acute myeloid leukemia.
Winters AC; Gutman JA; Purev E; Nakic M; Tobin J; Chase S; Kaiser J; Lyle L; Boggs C; Halsema K; Schowinsky JT; Rosser J; Ewalt MD; Siegele B; Rana V; Schuster S; Abbott D; Stevens BM; Jordan CT; Smith C; Pollyea DA
Blood Adv; 2019 Oct; 3(20):2911-2919. PubMed ID: 31648312
[TBL] [Abstract][Full Text] [Related]
16. Treatment outcomes of venetoclax-combination regimens for relapsed/refractory myeloid malignancies after anti-CD47-directed therapy.
Madero-Marroquin R; Dworkin E; Weiner H; Saygin C; Nawas MT; Drazer MW; DuVall AS; Kosuri S; Thirman MJ; Odenike O; Stock W; Larson RA; Patel AA
Leuk Lymphoma; 2024 Jun; 65(6):864-867. PubMed ID: 38441062
[No Abstract] [Full Text] [Related]
17. Daratumumab-based therapy after prior Azacytidine-Venetoclax in an octagenerian female with BPDCN (blastic plasmacytoid dendritic cell neoplasm) - a new perspective.
Mirgh S; Sharma A; Folbs B; Khushoo V; Kapoor J; Tejwani N; Ahmed R; Agrawal N; Choudhary PS; Mehta P; Bhurani D
Leuk Lymphoma; 2021 Dec; 62(12):3039-3042. PubMed ID: 34151693
[No Abstract] [Full Text] [Related]
18. Feasibility of the Combination of Venetoclax and Asparaginase-based Chemotherapy for Adult Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia.
El-Cheikh J; Moukalled NM; El Darsa H; Massoud R; Kanj SS; Mahfouz R; Bazarbachi A
Clin Lymphoma Myeloma Leuk; 2018 Oct; 18(10):e441-e444. PubMed ID: 30166258
[No Abstract] [Full Text] [Related]
19. Venetoclax and hypomethylating agents in older/unfit patients with blastic plasmacytoid dendritic cell neoplasm.
Gangat N; Konopleva M; Patnaik MM; Jabbour E; DiNardo C; Al-Kali A; Foran JM; Granroth GL; Olteanu H; Kadia T; Tefferi A; Pemmaraju N
Am J Hematol; 2022 Feb; 97(2):E62-E67. PubMed ID: 34807470
[No Abstract] [Full Text] [Related]
20. Venetoclax plus rituximab in relapsed or refractory chronic lymphocytic leukaemia: a phase 1b study.
Seymour JF; Ma S; Brander DM; Choi MY; Barrientos J; Davids MS; Anderson MA; Beaven AW; Rosen ST; Tam CS; Prine B; Agarwal SK; Munasinghe W; Zhu M; Lash LL; Desai M; Cerri E; Verdugo M; Kim SY; Humerickhouse RA; Gordon GB; Kipps TJ; Roberts AW
Lancet Oncol; 2017 Feb; 18(2):230-240. PubMed ID: 28089635
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
